The objective of this proposal is to coordinate the establishment of a European resource infrastructure of binding molecules directed against the entire human proteome. A major objective of the post-genome era is to detect, quantify and characterise all relevant human proteins in tissues and fluids in health and disease. This effort requires a comprehensive, characterised and standardised collection of specific ligand-binding reagents, including antibodies, the most widely used such molecules, and in addition novel protein scaffolds, nucleic acid aptamers, peptides and small chemical entitities. Currently there is no pan-European platform to coordinate systematic development, resource management and quality control for these important reagents. This CA will coordinate 26 European partners and two in the USA, several of which operate infrastructures or large-scale projects in aspects including cDNA collections, protein production, polyclonal and monoclonal antibodies. They provide a critical mass of leading expertise in binder technology, protein expression, binder applications and bioinformatics. Many have close links to relevant SMEs, as founders or advisors. The CA will plan the organisation of the resource, by integrating existing infrastructures, reviewing technologies and high.throughput production methods, standardising binder-based tools and applications, assembling bioinformatics and establishing a database schema for a central and applied research, impacting on healthcare, diagnostics, target discovery for drug intervention and therapeutics. It will thus be of great advantage to the research and biotechnology communities. In general terms, Europe is already well advanced in the technologies required and excellently placed to initiate this large scale project. The CA will prepare the way for an application for the production phase of the infrastructure under FP7.